⌕
Bio-Rad Laboratories · BIO · NYSE
Tenet 47 · Mixed
Compare
$358.19−0.57%At closeTenet 47 · Mixed
$358.19−2.07 (−0.57%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD

Bio-Rad Laboratories (BIO) Earnings Forecast

Analysts expect Bio-Rad Laboratories (BIO) to earn $9.98 a share in FY26, from the one published estimate as of Nov 16, 2026.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice

2 figures withheld by our checks. Each blank figure names its reason.

FY26 consensus EPS
$9.98
1 analyst
FY27 consensus EPS
$10.49
1 analyst · low $10.26, high $10.64
EPS revisions, 31 days
+2.4%
$9.75 to $9.98

Consensus estimates only. Analysts' price forecasts and ratings are not licensed here.

One analyst covers this company. Every figure on this page is that one person's estimate rather than an average of several, and it moves on one change of mind.

Consensus as of Nov 16, 2026 · we check it nightly

Analysts expect Bio-Rad Laboratories to earn $14.92 a share in FY30, growing about 11% a year; 1 analyst publishes an estimate for FY30.

Forward P/E · FY26E
36.1×
$360.26 (as of close, Nov 16, 2026) ÷ $9.98 consensus EPS
Range · FY26
None
low, high and average are one number
Coverage · FY26
1 · 2
EPS estimates · revenue estimates

Are estimates going up or down lately?

The FY26 EPS consensus is $9.98, up 3.5% in 90 days. Every figure compares one fiscal period at both ends.

EPS consensus, change over the last 90 days. One step per nightly change.

−1.8%+1.3%+4.4%FY26 +3.5%FY27 +1.3%Aug 18Nov 16
EPS30 days90 daysshown aboveSince Jul 6
FY261 analyst▲ +2.4%$9.75 to $9.98▲ +3.5%$9.64 to $9.98▲ +10.4%$9.04 to $9.98
FY271 analyst▼ −0.1%$10.50 to $10.49▲ +1.3%$10.35 to $10.49▲ +5.2%$9.96 to $10.49
Dec '261 analyst▼ −6.4%$3.02 to $2.83▼ −2.7%$2.91 to $2.83▼ −2.7%$2.91 to $2.83
Mar '271 analyst23 of 30 days−5.2% so far23 of 90 days−5.2% so far▼ −5.2%$2.98 to $2.83

Contributors at both ends of the window: FY26 2 and 1. A change in the average can come from a new contributor as much as from a changed mind, so both counts stay in view.

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

If the Street is right, what does that imply for the share price?

Price as of close, Nov 16, 2026 · consensus as of Nov 16, 2026

At 12.7 times earnings, which is what Bio-Rad Laboratories trades at today, the FY27 consensus of $10.49 works out to $134 a share.

Consensus EPS · FY27
$10.49
1 analyst · thin coverage
Multiple · today's trailing P/E
12.7×
We hold no filed EPS to divide the price by.
×
Receipt · BIO · FY27Nov 16, 2026
Implied, a share
$134

One analyst covers this year, so the estimate is a single number and there is no low to high band to draw around the answer.

10.49 × 12.7, to the dollar
Drag the multipleWe hold no fiscal-year P/E record for this company, so the track carries only the multiples we can name.
8×10×12×14×16×18×
today 12.7×$134 a share

Each point on the line is a multiple, and the flag is the price it implies for FY27. Past multiples are context, not a guide to future ones.

This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.

You are paying 36.1 times the FY26 consensus for earnings the one analyst covering it expects to grow about 9% a year to FY28. That is 4.0 times the growth rate.

How much do analysts disagree?

One analyst publishes on each year, so there is no range to draw: the low, the high and the average are one number, and a single mark stands for each year.

FY26E1 analyst
$9.76 to $10.13 · 3.6%
FY27E1 analyst
$10.26 to $10.64 · 3.6%
FY28E1 analyst
$11.62 to $12.05 · 3.6%
FY29E1 analyst
$12.98 to $13.46 · 3.6%
FY30E1 analyst
$14.59 to $15.13 · 3.6%

The dashed line is FY25 filed $27.85, on the GAAP basis.

A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average.

Is next quarter a high bar or an easy one?

Analysts expect Bio-Rad Laboratories to earn $2.83 a share in the December quarter, the one estimate published. Results are expected by Feb 16, 2027. Last quarter, which ended in September, Bio-Rad Laboratories earned $17.02 a share. Analysts had expected $2.23, so it came in 664.6% higher.

$26.59
$2.83high $2.83
low $2.83
−89.4%crosses bases
Dec 2025 quarterfiled · GAAPDec 2026 quarterconsensus · Street basis · 1 analyst
Expected report
Feb 16, 2027
Expected by Feb 16. An estimate, not a date the company has set. Companies move it.
Revenue expected · December quarter
$688.7M
1 analyst, 688.1 to 689.2 in $M · 693.2 in the same quarter a year ago

The step from a filed quarter to a consensus crosses bases: the filed figure is the company's own GAAP number and the consensus is on the Street's basis. It is printed with both bases named, not as growth. For the March quarter, analysts expect $2.83 a share.

Does Bio-Rad Laboratories usually beat or miss?

So far we have checked 5 quarters, of which 5 came in above the estimate we held. We add a quarter to this record each time Bio-Rad Laboratories reports. The next report is expected by Feb 16, 2027.

We started recording estimates on Jul 6, 2026, so quarters that reported before that date cannot be checked.

Before our record
Dec '23
Our record, one quarter per report
+526.7%
Mar '24reaction
−4.2%
Jun '24left out · basis
Sep '24left out · basis
Dec '24left out · basis
+26.5%
Mar '25reaction
−1.7%
+573.0%
Jun '25reaction
+17.6%
Sep '25left out · adjusted
Dec '25left out · basis
Mar '26left out · basis
+692.5%
Jun '26reaction
+4.5%
+664.6%
Sep '26reaction
−2.9%
reportsFeb 16
Dec '26
Checked so far
5 quarters
one more every report
Beat expectations
5 of 5
full details on the Earnings tab
Share price reaction
Not held
we hold no measured reaction for the quarters we have checked
Typical gap vs estimate
+573.0%
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for Bio-Rad Laboratories on Jul 6, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact. Mar '24, Mar '25, Jun '25 are drawn hollow: we hold no estimate for those quarters recorded strictly before the report, so it is scored against the last estimate we hold rather than the night-before one.

The one analyst covering it expects sales to grow 2.2% in FY27 and EPS 5.0%. Sales are part of it: the net margin moves from 10.5% to 10.8%, and the implied share count from about 27.2M to 27.2M, so these numbers assume the count stands still.Show the decomposition and the margin ladderHide the decomposition
FY27 EPS growth, in points
Revenue growth+2.2
Net margin change+2.8
Share count change0.0
EPS growth+5.0
Legs are rounded to a tenth of a point and the largest remainder carries the difference, so they add to the total. Implied shares = consensus net income ÷ consensus EPS, a direction rather than a decimal.
1 analyst publishes an EPS estimate for FY26 and 2 publish revenue. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by year and over timeHide the coverage chart
Analysts by fiscal year · outlined revenue, filled EPS. Amber marks a panel of fewer than 15.
21
FY26E
21
FY27E
21
FY28E
11
FY29E
11
FY30E
The FY26 panel held 2 analysts when our record of it began on Jul 6, 2026 and holds 1 tonight.

The full consensus, year by year

Consensus as of Nov 16, 2026 · filed figures as reported
Revenue · $Bfiled · consensus average · band = low to high
2.52.72.9historyStreet forecastFY22FY25FY30E

Coverage thins with distance: 2 revenue estimates for FY26, 1 for FY30.

Diluted EPS · $filed · consensus average · band = low to high
−70.95−19.6931.58historyStreet forecastFY22FY25FY30E

Out-year bands widen as fewer analysts publish: 1 EPS estimates for FY26, 1 for FY30.

Fiscal yearRevenue $BYoYEPS $YoYEBITDA $BNet inc. $BShares BAnalysts rev · EPSFwd P/E
FY25Filed2.6—27.85————as filed12.7×
FY26E2.62.5 to 2.6▲0.2%a9.989.76 to 10.13▼64.2%a0.60.30.032 · 136.1×
FY27E2.62.6 to 2.7▲2.2%10.4910.26 to 10.64▲5.0%0.60.30.032 · 134.4×
FY28E2.72.6 to 2.8▲2.9%11.8811.62 to 12.05▲13.3%0.60.30.032 · 130.3×
FY29E2.82.7 to 2.8n/cb13.2712.98 to 13.46▲11.7%0.70.40.031 · 127.1×
FY30E2.92.8 to 2.9▲2.8%14.9214.59 to 15.13▲12.4%0.70.40.031 · 124.1×

Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over that year's filed EPS, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 1 EPS estimates for FY26, 2 for revenue. Not investment advice.

What do analysts expect Bio-Rad Laboratories to earn in FY26?

The one analyst covering Bio-Rad Laboratories expects it to earn $9.98 a share in FY26, as of Nov 16, 2026.

What is Bio-Rad Laboratories' earnings forecast for FY27?

The FY27 consensus for Bio-Rad Laboratories is $10.49 a share from 1 analyst, as of Nov 16, 2026.

Have analysts raised Bio-Rad Laboratories' earnings estimates?

Bio-Rad Laboratories' FY26 EPS consensus rose 3.5% in 90 days, from $9.64 to $9.98, as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.